TetraLogic Pharmaceuticals Corp
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to… Read more
TetraLogic Pharmaceuticals Corp (TLOG) - Net Assets
Latest net assets as of September 2016: $-30.94 Million USD
Based on the latest financial reports, TetraLogic Pharmaceuticals Corp (TLOG) has net assets worth $-30.94 Million USD as of September 2016.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($42.79 Million) and total liabilities ($73.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-30.94 Million |
| % of Total Assets | -72.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 41.93 |
TetraLogic Pharmaceuticals Corp - Net Assets Trend (2011–2015)
This chart illustrates how TetraLogic Pharmaceuticals Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TetraLogic Pharmaceuticals Corp (2011–2015)
The table below shows the annual net assets of TetraLogic Pharmaceuticals Corp from 2011 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $-5.94 Million | -117.79% |
| 2014-12-31 | $33.40 Million | -33.92% |
| 2013-12-31 | $50.55 Million | +173.86% |
| 2012-12-31 | $-68.44 Million | -30.13% |
| 2011-12-31 | $-52.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TetraLogic Pharmaceuticals Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12183287900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.48K | % |
| Other Comprehensive Income | $-71.76K | % |
| Other Components | $169.68 Million | % |
| Total Equity | $-5.94 Million | 100.00% |
TetraLogic Pharmaceuticals Corp Competitors by Market Cap
The table below lists competitors of TetraLogic Pharmaceuticals Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Armstrong Flooring Inc
OTCMKTS:AFIIQ
|
$2.18K |
|
THMY Holdings Berhad
KLSE:0375
|
$2.18K |
|
LINDSAY AUSTRALIA
BE:J3B
|
$2.18K |
|
Ebiquity Plc
LSE:EBQ
|
$2.18K |
|
PRIMAG (P9R.SG)
STU:P9R
|
$2.18K |
|
ELEMENTOS (9EM.SG)
STU:9EM
|
$2.18K |
|
CANFOR PULP (8CP.SG)
STU:8CP
|
$2.17K |
|
PaxMedica, Inc. Common Stock
PINK:PXMD
|
$2.17K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TetraLogic Pharmaceuticals Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from 33,402,176 to -5,940,726, a change of -39,342,902 (-117.8%).
- Net loss of 56,108,339 reduced equity.
- Share repurchases of 31,201 reduced equity.
- Other comprehensive income increased equity by 5,387.
- Other factors increased equity by 16,791,251.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.11 Million | -944.47% |
| Share Repurchases | $31.20K | -0.53% |
| Other Comprehensive Income | $5.39K | +0.09% |
| Other Changes | $16.79 Million | +282.65% |
| Total Change | $- | -117.79% |
Book Value vs Market Value Analysis
This analysis compares TetraLogic Pharmaceuticals Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-41.14 | $0.00 | x |
| 2012-12-31 | $-70.55 | $0.00 | x |
| 2013-12-31 | $22.02 | $0.00 | x |
| 2014-12-31 | $1.49 | $0.00 | x |
| 2015-12-31 | $-0.25 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TetraLogic Pharmaceuticals Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-32.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.67 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.43 Million |
| 2013 | -44.94% | 0.00% | 0.00x | 1.10x | $-27.77 Million |
| 2014 | -117.71% | 0.00% | 0.00x | 3.54x | $-42.66 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-55.51 Million |
Industry Comparison
This section compares TetraLogic Pharmaceuticals Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TetraLogic Pharmaceuticals Corp (TLOG) | $-30.94 Million | 0.00% | N/A | $2.18K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |